Regulus Therapeutics Inc’s recent filing unveils that its Chief Executive Officer Hagan Joseph P unloaded Company’s shares for reported $17359.0 on Jan 18 ’24. In the deal valued at $1.19 per share,14,580 shares were sold. As a result of this transaction, Hagan Joseph P now holds 57,112 shares worth roughly $0.15 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, CALSADA CRISPINA sold 5,468 shares, generating $6,510 in total proceeds. Upon selling the shares at $1.19, the Chief Financial Officer now owns 5,782 shares.
Before that, Aker Christopher Ray sold 5,468 shares. Regulus Therapeutics Inc shares valued at $6,510 were divested by the Sr. VP & General Counsel at a price of $1.19 per share. As a result of the transaction, Aker Christopher Ray now holds 10,056 shares, worth roughly $26950.08.
Leerink Partners initiated its Regulus Therapeutics Inc [RGLS] rating to an Outperform in a research note published on March 18, 2024; the price target was $6. A number of analysts have revised their coverage, including B. Riley FBR Inc.’s analysts, who began to cover the stock in late March with a ‘”a Neutral”‘ rating. Leerink Partners began covering RGLS with “an Outperform” recommendation on January 05, 2018. Chardan Capital Markets maintained its rating on June 13, 2017. It rated RGLS as “a Buy”.
Price Performance Review of RGLS
On Friday, Regulus Therapeutics Inc [NASDAQ:RGLS] saw its stock fall -3.42% to $2.68. Over the last five days, the stock has gained 27.25%. Regulus Therapeutics Inc shares have risen nearly 109.77% since the year began. Nevertheless, the stocks have risen 158.17% over the past one year. While a 52-week high of $3.79 was reached on 03/12/24, a 52-week low of $0.77 was recorded on 01/17/24. SMA at 50 days reached $1.58, while 200 days put it at $1.44. A total of 0.7 million shares were traded, compared to the trading of 1.47 million shares in the previous session.
Levels Of Support And Resistance For RGLS Stock
The 24-hour chart illustrates a support level at 2.55, which if violated will result in even more drops to 2.41. On the upside, there is a resistance level at 2.83. A further resistance level may holdings at 2.97. The Relative Strength Index (RSI) on the 14-day chart is 72.91, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 44.74%. Stochastics %K at 54.05% indicates the stock is a holding.
How much short interest is there in Regulus Therapeutics Inc?
A steep rise in short interest was recorded in Regulus Therapeutics Inc stocks on Feb 29, 2024, dropping by 61420.0 shares to a total of 54880.0 shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 0.12 million shares. There was a decline of -111.92%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.35% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.03.
The most recent change occurred on March 06, 2017 when Wedbush resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $6.
